AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Trading 06-26 10:23:13

83.300

-2.150

-2.52%

High86.500	Low82.600	Vol4.18M
Open86.000	D1 Closing85.450	Amplitude4.56%
Mkt Cap76.72B	Tradable Cap76.72B	Total Shares921.00M
T/O352.82M	T/O Rate0.45%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":83.3,"timestamp":1782440592365,"preClose":85.45,"halted":0,"volume":4176684,"delay":0,"changeRate":-0.025160912814511476,"floatShares":921000000,"shares":921000000,"eps":-1.420942384213663,"marketStatus":"Trading","change":-2.15,"latestTime":"06-26 10:23:13","open":86,"high":86.5,"low":82.6,"amount":352816481,"amplitude":0.045641,"askPrice":83.3,"askSize":10000,"bidPrice":83.25,"bidSize":20000,"shortable":3,"etf":0,"ttmEps":-1.420942384213663,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1782446400000},"marketStatusCode":2,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":85.45,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":1.638122,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.6644,"impliedVolPercentile":0.7925},"requestUrl":"/m/hq/s/09926/","defaultTab":"news","newsList":[{"id":"1189038270","title":"Movement Alert｜Akeso Falls 3.43% in Regular Trading, Post-ASCO Profit-Taking Persists as Biotech Sector Weakens Again","url":"https://stock-news.laohu8.com/highlight/detail?id=1189038270","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189038270?lang=en_us&edition=fundamental","pubTime":"2026-06-25 09:56","pubTimestamp":1782352603,"startTime":"0","endTime":"0","summary":"On June 25, Akeso (09926.HK) fell 3.43% in regular trading, trading at HK$84.25/share, with turnover of HK$188 million. The stock is approaching its previous 52-week low zone.On the news front, the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102387263","title":"Movement Alert｜Akeso Rises 3.1% in Regular Trading, Multiple Brokerages Issue Buy Ratings Amid Biotech Sector Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1102387263","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102387263?lang=en_us&edition=fundamental","pubTime":"2026-06-24 09:49","pubTimestamp":1782265763,"startTime":"0","endTime":"0","summary":"On June 24, Akeso (09926.HK) rose 3.1% in regular trading, trading at HKD 88.4/share, with turnover of HKD 262 million.On the news front, CITIC Construction Investment and Industrial Securities...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100407015","title":"Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies","url":"https://stock-news.laohu8.com/highlight/detail?id=1100407015","media":"Stock News","labels":["policyRegulatory","economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100407015?lang=en_us&edition=fundamental","pubTime":"2026-06-23 11:46","pubTimestamp":1782186399,"startTime":"0","endTime":"0","summary":"Shares in the innovative drug sector experienced a broad-based rally today.At the time of writing, SSY GROUP (02005) was up 6.93% at HK$2.16, KEYMED BIO-B (02162) gained 4.14% to HK$59.05, HENGRUI...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory,economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828557.USD","LU2476274720.SGD","LU0417516571.SGD","LU0417516738.SGD","LU1794554557.SGD","BK1583","BK1589","LU0348767384.USD","LU0348784397.USD","159938","LU2543165471.USD","06978","09926","LU2097828714.EUR","HK0000165453.HKD","01276","LU2460026573.USD","LU0561508036.HKD","LU2097828631.EUR","02005","LU2488822045.USD","LU2097828805.USD","LU1961090484.USD","LU0348735423.USD","LU1969619763.USD","BK1587","LU0359201612.USD","LU0540923850.HKD","LU2097828474.EUR","BK1191","LU0417516902.SGD","LU2399975544.HKD","01801","LU0348766576.USD","02162","LU2778985437.USD","LU0348827113.USD","BK1574","LU0502904849.HKD","LU2476274308.USD","159992","BK1515","LU1023057109.AUD","IE00B543WZ88.USD","BK4585","LU0634319403.HKD","LU0359202008.SGD","LU1720050803.USD","VXUS","LU2242644610.SGD","BK4588","LU2328871848.SGD","BK1161","LU0455707207.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU0359201885.HKD","LU0348783233.USD","LU0348825331.USD","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169428216","title":"China Securities Research Initiates Coverage on AKESO with a \"Buy\" Rating, Citing Multiple Growth Drivers","url":"https://stock-news.laohu8.com/highlight/detail?id=1169428216","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169428216?lang=en_us&edition=fundamental","pubTime":"2026-06-23 10:31","pubTimestamp":1782181863,"startTime":"0","endTime":"0","summary":"China Securities has issued a research report initiating coverage on AKESO (09926) with a \"Buy\" rating, citing the excellent efficacy and broad market potential of the company's innovative drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU0417516738.SGD","LU0417516571.SGD","LU0348825331.USD","LU2476274720.SGD","IE00BPRC5H50.USD","LU2778985437.USD","LU0348783233.USD","LU0561508036.HKD","LU0348766576.USD","LU1720050803.USD","LU2488822045.USD","BK1161","LU0540923850.HKD","IE00B5MMRT66.SGD","LU1961090484.USD","LU0348827113.USD","09926","LU2476274308.USD","LU0634319403.HKD","LU0348767384.USD","LU0348784397.USD","LU1794554557.SGD","BK1574","LU0417516902.SGD","LU2399975544.HKD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170628820","title":"Movement Alert｜Akeso Rises 3.44% in Regular Trading, Buyback Support and Broker Buy Rating Trigger Rebound Near 52-Week Low","url":"https://stock-news.laohu8.com/highlight/detail?id=1170628820","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170628820?lang=en_us&edition=fundamental","pubTime":"2026-06-23 09:39","pubTimestamp":1782178770,"startTime":"0","endTime":"0","summary":"On June 23, Akeso rose 3.44% in regular trading, trading at HK$86.1/share, with turnover of HK$135 million. On the news front, the stock approached its 52-week low of HK$82.85 in the previous...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144807194","title":"Movement Alert｜Akeso Inc Falls 3.88% in Regular Trading, Sustained Selling Pressure Post-ASCO Data as Buyback Fails to Reverse Trend","url":"https://stock-news.laohu8.com/highlight/detail?id=1144807194","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144807194?lang=en_us&edition=fundamental","pubTime":"2026-06-22 09:45","pubTimestamp":1782092741,"startTime":"0","endTime":"0","summary":"On June 22, Akeso Inc (09926.HK) fell 3.88% in regular trading, trading at HK$82.45/share with turnover of HK$169 million, approaching its 52-week low of HK$82.85.The decline reflects continued...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644527520","title":"Akeso (SEHK:9926) Stock Could Be 49% Undervalued After New AML Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2644527520","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644527520?lang=en_us&edition=fundamental","pubTime":"2026-06-19 18:38","pubTimestamp":1781865481,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) is back in focus after presenting Phase II data for its anti CD47 antibody ligufalimab in acute myeloid leukemia at the 2026 European Hematology Association Congress, highlighting survival and response outcomes versus standard therapy.\nSee our latest analysis for Akeso.\nAkeso's HK$87.55 share price has seen a 4.35% 1 day gain but is still down 22.38% over 30 days and 24.26% over 90 days. The 3 year total shareholder return of 152.67% contrasts with a 4.89% decline over the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-stock-could-be-49-undervalued-after-new-aml-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-stock-could-be-49-undervalued-after-new-aml-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0561508036.HKD","LU2778985437.USD","IE00B543WZ88.USD","LU0348735423.USD","IE00BPRC5H50.USD","LU2399975544.HKD","BK1574","BK1161","IE00B5MMRT66.SGD","LU0348766576.USD","LU0634319403.HKD","09926","LU1794554557.SGD","LU2476274308.USD","LU1720050803.USD","LU2476274720.SGD","LU0348767384.USD","LU0417516902.SGD","LU0540923850.HKD","LU0417516571.SGD","LU2488822045.USD","LU0417516738.SGD","LU0348827113.USD","LU0348783233.USD","LU0348784397.USD","LU0348825331.USD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179848973","title":"Movement Alert｜Akeso Rises 3.64% in Regular Trading, Industry Buyback Wave and Sector Oversold Rebound Support Price Stabilization","url":"https://stock-news.laohu8.com/highlight/detail?id=1179848973","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179848973?lang=en_us&edition=fundamental","pubTime":"2026-06-18 10:06","pubTimestamp":1781748383,"startTime":"0","endTime":"0","summary":"On June 18, Akeso (9926.HK) rose 3.64% in regular trading, trading at HK$88.3 per share, with turnover of HK$273 million.On the news front, an ongoing wave of share buybacks across the pharmaceutical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644718934","title":"Akeso says Phase II trial shows ligufalimab plus azacitidine, venetoclax extends event-free survival in frontline AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2644718934","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644718934?lang=en_us&edition=fundamental","pubTime":"2026-06-17 13:40","pubTimestamp":1781674814,"startTime":"0","endTime":"0","summary":"Akeso reported Phase II results already presented at the 2026 EHA Congress for ligufalimab with azacitidine, venetoclax in frontline AML.The combination showed longer survival outcomes than the control regimen in treatment-nave patients ineligible for intensive chemotherapy.Responses were deeper and lasted longer, with more patients reaching remission without detectable residual disease.Safety looked broadly comparable with the control arm, with no new safety signals flagged.Ligufalimab already holds FDA orphan-drug designation in AML, supporting a broader development push across blood cancers, solid tumors.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL9nGXYy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU0417516738.SGD","LU1961090484.USD","09926","LU0561508036.HKD","LU0634319403.HKD","LU1794554557.SGD","LU0348825331.USD","LU0417516571.SGD","LU0540923850.HKD","LU1720050803.USD","IE00B5MMRT66.SGD","LU0348784397.USD","BK1161","LU0348735423.USD","LU0417516902.SGD","LU0348783233.USD","LU0348827113.USD","LU0348766576.USD","LU2476274308.USD","BK1574","LU2778985437.USD","LU2476274720.SGD","IE00B543WZ88.USD","LU2399975544.HKD","LU0348767384.USD","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181557700","title":"Movement Alert｜Akeso Falls 3.41% in Regular Trading, Buyback Plan Fails to Halt Post-ASCO Profit-Taking Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=1181557700","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181557700?lang=en_us&edition=fundamental","pubTime":"2026-06-16 09:39","pubTimestamp":1781573986,"startTime":"0","endTime":"0","summary":"On June 16, Akeso (09926.HK) fell 3.41% in regular trading, trading at HK$86.1/share, with turnover of HK$118 million. The stock has now declined over 30% from its post-ASCO data release high.On the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643022079","title":"Akeso enrolls first patient in Phase Ib/II study of HER3 ADC AK138D1 plus ivonescimab in advanced breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2643022079","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643022079?lang=en_us&edition=fundamental","pubTime":"2026-06-15 14:53","pubTimestamp":1781506397,"startTime":"0","endTime":"0","summary":"Akeso enrolled the first patient in a Phase Ib/II study of HER3 ADC AK138D1, alone or with ivonescimab, in advanced breast cancer.No new trial results were presented; the study will generate future data to support the company’s IO2.0 and ADC2.0 development strategy.The program targets HR+/HER2- and triple-negative breast cancer, aiming to address unmet need across earlier-line and heavily pretreated patients.Prior early-stage studies in China and Australia indicated anti-tumor activity with a favorable tolerability profile, supporting broader combination testing.The combination could strengthen Akeso’s pipeline positioning as IO-ADC regimens draw higher investment and partnering interest across oncology.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL93WBfM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516571.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU0348766576.USD","LU0348783233.USD","LU0634319403.HKD","LU0348735423.USD","LU1961090484.USD","LU2778985437.USD","LU0348827113.USD","LU2476274308.USD","LU0348825331.USD","LU0561508036.HKD","LU0417516902.SGD","LU1794554557.SGD","LU2476274720.SGD","LU0540923850.HKD","LU0417516738.SGD","LU0348767384.USD","LU0348784397.USD","BK1161","LU2488822045.USD","LU2399975544.HKD","LU1720050803.USD","IE00B5MMRT66.SGD","09926","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643766220","title":"Akeso's Next-Generation Her3 ADC Ak138d1 Combined With Ivonescimab: First Patient Enrolled in Phase Ib/Ii Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2643766220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643766220?lang=en_us&edition=fundamental","pubTime":"2026-06-15 14:53","pubTimestamp":1781506380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA9QHR9F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","LU0348827113.USD","LU1720050803.USD","LU0348784397.USD","LU0540923850.HKD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU1961090484.USD","LU0348735423.USD","LU1794554557.SGD","LU2399975544.HKD","LU0634319403.HKD","LU2476274308.USD","LU2778985437.USD","LU0561508036.HKD","09926","BK1161","IE00B543WZ88.USD","LU0348767384.USD","LU0417516738.SGD","LU0348825331.USD","LU2488822045.USD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0348766576.USD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109054535","title":"Movement Alert｜Akeso Bio Falls 3.04% in Regular Trading, Post-ASCO Selling Pressure Resumes After Brief Buyback-Driven Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=1109054535","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109054535?lang=en_us&edition=fundamental","pubTime":"2026-06-15 14:23","pubTimestamp":1781504608,"startTime":"0","endTime":"0","summary":"On June 15, Akeso Bio (09926.HK) fell 3.04% in regular trading, trading at HK$89.3/share, with turnover of HK$1.363 billion.The decline follows the company's board approval of a share repurchase plan...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149995644","title":"AKESO's Novel Drug AK111 Receives Marketing Authorization from Chinese Regulators for Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=1149995644","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149995644?lang=en_us&edition=fundamental","pubTime":"2026-06-12 17:14","pubTimestamp":1781255674,"startTime":"0","endTime":"0","summary":"AKESO has announced that its drug Qiyoukang® (Gumoqimab, AK111) has received marketing approval from China's National Medical Products Administration (NMPA) for the treatment of moderate to severe...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU0540923850.HKD","LU0348827113.USD","LU0348767384.USD","LU0417516902.SGD","LU2476274720.SGD","IE00BPRC5H50.USD","LU2778985437.USD","IE00B543WZ88.USD","BK1161","09926","LU0348735423.USD","IPOS","LU0348784397.USD","LU0417516571.SGD","BK1574","LU0348825331.USD","LU2476274308.USD","LU2399975544.HKD","LU0634319403.HKD","LU1794554557.SGD","IE00B5MMRT66.SGD","LU0348783233.USD","LU1720050803.USD","LU2488822045.USD","LU0348766576.USD","LU1961090484.USD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642266784","title":"Akeso - Nmpa Approves New Drug Application for Gumokimab (Ak111)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642266784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642266784?lang=en_us&edition=fundamental","pubTime":"2026-06-12 17:07","pubTimestamp":1781255273,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nFWN42K066:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0417516902.SGD","LU0561508036.HKD","LU2488822045.USD","LU0540923850.HKD","IE00B543WZ88.USD","BK1161","LU0417516738.SGD","IE00B5MMRT66.SGD","09926","LU0348827113.USD","LU0348784397.USD","LU1961090484.USD","LU2399975544.HKD","LU0634319403.HKD","LU1794554557.SGD","LU2476274308.USD","LU0348766576.USD","LU0348825331.USD","LU0348735423.USD","LU0348767384.USD","LU0417516571.SGD","LU2476274720.SGD","LU1720050803.USD","LU0348783233.USD","IE00BPRC5H50.USD","LU2778985437.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167015341","title":"Movement Alert｜Akeso Bio Rises 3.13% in Regular Trading, Board Approves HK$200 Million Buyback Plan and Management Pledges HK$50 Million in Open-Market Purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=1167015341","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167015341?lang=en_us&edition=fundamental","pubTime":"2026-06-12 10:10","pubTimestamp":1781230203,"startTime":"0","endTime":"0","summary":"On June 12, Akeso Bio rose 3.13% in regular trading, trading at HK$89.35/share, with turnover of HK$356 million. The rebound follows a significant corporate action announced the prior day.On June 11,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642525543","title":"Akeso says China NMPA approves gumokimab for moderate-to-severe plaque psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2642525543","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642525543?lang=en_us&edition=fundamental","pubTime":"2026-06-12 09:58","pubTimestamp":1781229484,"startTime":"0","endTime":"0","summary":"China’s NMPA cleared Akeso’s gumokimab  for adults with moderate-to-severe plaque psoriasis.Regulators accepted a supplemental NDA for gumokimab in active ankylosing spondylitis for review.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDLc6YN28:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU0348825331.USD","LU2399975544.HKD","09926","LU0348766576.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU0348767384.USD","LU0634319403.HKD","LU2476274720.SGD","LU0348784397.USD","LU2488822045.USD","LU1794554557.SGD","LU1720050803.USD","IE00B543WZ88.USD","LU0561508036.HKD","LU2778985437.USD","LU2476274308.USD","LU0417516738.SGD","LU0348827113.USD","LU0348783233.USD","BK1574","IE00B5MMRT66.SGD","LU0348735423.USD","LU1961090484.USD","LU0417516571.SGD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642128284","title":"Akeso's Trustee, Senior Management to Buy Back Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642128284","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642128284?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:35","pubTimestamp":1781181356,"startTime":"0","endTime":"0","summary":"Akeso's  board approved a plan for a trustee to buy back up to HK$200 million ordinary shares under a 2021 restricted share unit scheme, according to a Thursday Hong Kong bourse filing.The shares will be repurchased from the open market, the drug company said.Additionally, Chairperson and CEO Xia Yu, Chief Financial Officer Bing C. Wang, and three executive directors plan to increase their shareholdings in the company.The parties will purchase a total of up to HK$50 million shares from the open market.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0348783233.USD","LU0417516738.SGD","LU2476274308.USD","IE00B543WZ88.USD","LU0348766576.USD","LU1794554557.SGD","LU0348767384.USD","LU2778985437.USD","LU0348825331.USD","IE00BPRC5H50.USD","LU1961090484.USD","LU2488822045.USD","LU0417516571.SGD","LU0348735423.USD","LU0561508036.HKD","LU1720050803.USD","LU0634319403.HKD","LU2476274720.SGD","BK1574","LU0348784397.USD","BK1161","09926","LU0540923850.HKD","LU0417516902.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642405449","title":"Akeso Board Approves HK$200 Million Share Purchase Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2642405449","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642405449?lang=en_us&edition=fundamental","pubTime":"2026-06-11 12:47","pubTimestamp":1781153248,"startTime":"0","endTime":"0","summary":"Akeso's  board approved a plan to purchase up to HK$200 million of its shares on the open market, according to a Thursday Hong Kong bourse filing.The purchases will be conducted through the trustee of the company's 2021 restricted share unit scheme and will be funded by existing cash resources.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BPRC5H50.USD","09926","LU0348735423.USD","LU0348825331.USD","LU0348783233.USD","LU0348766576.USD","IE00B543WZ88.USD","LU1720050803.USD","LU0348784397.USD","LU0348827113.USD","LU0417516571.SGD","LU0417516738.SGD","LU2488822045.USD","LU0348767384.USD","LU2399975544.HKD","LU0634319403.HKD","LU0540923850.HKD","BK1574","LU1794554557.SGD","BK1161","LU2476274308.USD","LU0417516902.SGD","LU2476274720.SGD","LU0561508036.HKD","LU1961090484.USD","IE00B5MMRT66.SGD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103869830","title":"Akeso Announces HK$200.00 Million Share Buyback and HK$50.00 Million Insider Purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=1103869830","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103869830?lang=en_us&edition=fundamental","pubTime":"2026-06-11 12:21","pubTimestamp":1781151714,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (Stock Code: 09926) disclosed that its board has approved the deployment of up to HK$200.00 million in existing cash to repurchase ordinary shares on the open market. The buyback will be...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.2384},{"period":"3month","weight":-0.324},{"period":"6month","weight":-0.2411},{"period":"1year","weight":-0.1285},{"period":"ytd","weight":-0.2438}],"compareEarnings":[{"period":"1week","weight":-0.0354},{"period":"1month","weight":-0.0985},{"period":"3month","weight":-0.0751},{"period":"6month","weight":-0.1062},{"period":"1year","weight":-0.0571},{"period":"ytd","weight":-0.0996}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.074707},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}